Bellevue Group AG reported 142 positions worth $4.52B for the quarter ended Jun 30, 2026, up 13.8% on the prior quarter. It opened 16 new positions, added to 40, trimmed 65 and exited 22. Its largest holding is Amgen Inc at 6.8% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| AMGN Amgen Inc | +556.2K | +188.3% | $201.41M | 6.82% |
| INSM INSMED Inc | +1.38M | +13,787.0% | $147.50M | 3.29% |
| GILD Gilead Sciences, Inc. | +988.9K | +84.5% | $124.94M | 6.03% |
| ORKA Oruka Therapeutics, Inc. | +1.15M | +226.9% | $109.46M | 3.49% |
| UTHR UNITED THERAPEUTICS Corp | +186.4K | +8,976.3% | $101.02M | 2.26% |
| BBIO BridgeBio Pharma, Inc. | +1.16M | +4,587.3% | $86.70M | 1.96% |
| PCVX Vaxcyte, Inc. | +781.2K | +65.6% | $45.41M | 2.54% |
| AVLN Avalyn Pharma Inc. | +1.35M | – | $44.44M | 0.983% |
| CGON CG Oncology, Inc. | +493.6K | – | $35.07M | 0.776% |
| SPTX Seaport Therapeutics, Inc. | +1.10M | – | $23.89M | 0.529% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| KRYS Krystal Biotech, Inc. | -404.3K | -83.9% | $150.25M | 0.638% |
| RVMD Revolution Medicines, Inc. | -496.4K | -32.1% | $92.97M | 4.34% |
| REGN Regeneron Pharmaceuticals, Inc. | -121.4K | -43.6% | $75.69M | 2.17% |
| ALNY Alnylam Pharmaceuticals, Inc. | -233.5K | -99.5% | $70.28M | <0.01% |
| IONS Ionis Pharmaceuticals Inc | -846.4K | -46.5% | $67.11M | 1.71% |
| SRRK Scholar Rock Holding Corp | -1.14M | -31.7% | $62.43M | 2.98% |
| TNGX Tango Therapeutics, Inc. | -1.71M | -71.1% | $53.32M | 0.48% |
| VRTX Vertex Pharmaceuticals Inc / Ma | -103.3K | -15.1% | $51.30M | 6.36% |
| EWTX Edgewise Therapeutics, Inc. | -1.53M | -100.0% | $48.15M | Exited |
| ELVN Enliven Therapeutics, Inc. | -830.9K | -35.8% | $42.17M | 1.67% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| AVLN Avalyn Pharma Inc. | +1.35M | $44.44M | 0.983% |
| CGON CG Oncology, Inc. | +493.6K | $35.07M | 0.776% |
| SPTX Seaport Therapeutics, Inc. | +1.10M | $23.89M | 0.529% |
| PVLA Palvella Therapeutics, Inc. | +155.0K | $23.69M | 0.524% |
| SYRE Spyre Therapeutics, Inc. | +229.9K | $20.41M | 0.452% |
| COAG Hemab Therapeutics Holdings, Inc. | +550.0K | $20.20M | 0.447% |
| PBLS Parabilis Medicines, Inc. | +500.0K | $13.69M | 0.303% |
| AURA Aura Biosciences, Inc. | +1.17M | $8.28M | 0.183% |
| MOH Molina Healthcare, Inc. | +27.8K | $6.35M | 0.14% |
| GMRS GMR Solutions Inc. | +333.3K | $5.15M | 0.114% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| EWTX Edgewise Therapeutics, Inc. | -1.53M | $48.15M | 1.21% |
| INSP Inspire Medical Systems, Inc. | -99.7K | $5.14M | 0.13% |
| PEN Penumbra Inc | -12.3K | $4.03M | 0.101% |
| RNA Atrium Therapeutics, Inc. | -263.1K | $3.52M | 0.089% |
| EQNR Equinor Asa | -17.6K | $741.58K | 0.019% |
| XOM ExxonMobil Holdings Corp | -4,370 | $741.41K | 0.019% |
| BP Bp Plc | -15.6K | $735.27K | 0.019% |
| SHEL Shell plc | -7,844 | $729.49K | 0.018% |
| CSCO Cisco Systems, Inc. | -8,000 | $620.72K | 0.016% |
| BABA Alibaba Group Holding Ltd | -4,700 | $589.66K | 0.015% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | AMGN Amgen Inc | Healthcare | 851.6K | $308.36M | 6.82% | +556.2K | +188.3% | Added | 0.16% |
| 2 | VRTX Vertex Pharmaceuticals Inc / Ma | Healthcare | 578.6K | $287.42M | 6.36% | -103.3K | -15.1% | Reduced | 0.23% |
| 3 | ARGX Argenx Se | Healthcare | 301.0K | $279.26M | 6.18% | -12.0K | -3.8% | Reduced | 0.49% |
| 4 | GILD Gilead Sciences, Inc. | Healthcare | 2.16M | $272.74M | 6.03% | +988.9K | +84.5% | Added | 0.17% |
| 5 | RVMD Revolution Medicines, Inc. | Healthcare | 1.05M | $196.27M | 4.34% | -496.4K | -32.1% | Reduced | 0.49% |
| 6 | ORKA Oruka Therapeutics, Inc. | Healthcare | 1.66M | $157.71M | 3.49% | +1.15M | +226.9% | Added | 2.64% |
| 7 | INSM INSMED Inc | Healthcare | 1.39M | $148.57M | 3.29% | +1.38M | +13,787.0% | Added | 0.64% |
| 8 | SRRK Scholar Rock Holding Corp | Healthcare | 2.45M | $134.73M | 2.98% | -1.14M | -31.7% | Reduced | 1.88% |
| 9 | VRDN Viridian Therapeutics, Inc.\DE | Healthcare | 6.73M | $123.67M | 2.74% | +5,765 | +0.1% | Added | 5.94% |
| 10 | RLAY Relay Therapeutics, Inc. | Healthcare | 6.19M | $115.74M | 2.56% | -1.61M | -20.6% | Reduced | 2.83% |
| 11 | PCVX Vaxcyte, Inc. | Healthcare | 1.97M | $114.63M | 2.54% | +781.2K | +65.6% | Added | 1.36% |
| 12 | UTHR UNITED THERAPEUTICS Corp | Healthcare | 188.5K | $102.14M | 2.26% | +186.4K | +8,976.3% | Added | 0.44% |
| 13 | ISRG Intuitive Surgical Inc | Healthcare | 254.8K | $101.33M | 2.24% | -31.8K | -11.1% | Reduced | 0.07% |
| 14 | REGN Regeneron Pharmaceuticals, Inc. | Healthcare | 157.3K | $98.08M | 2.17% | -121.4K | -43.6% | Reduced | 0.11% |
| 15 | BBIO BridgeBio Pharma, Inc. | Healthcare | 1.19M | $88.59M | 1.96% | +1.16M | +4,587.3% | Added | 0.61% |
Tip. Select a row to see that position’s full history at Bellevue Group AG.
As of its Q2 2026 13F filing, Bellevue Group AG’s five largest positions were Amgen Inc (AMGN) at 6.8%, Vertex Pharmaceuticals Inc / Ma (VRTX) at 6.4%, Argenx Se (ARGX) at 6.2%, Gilead Sciences, Inc. (GILD) at 6.0%, Revolution Medicines, Inc. (RVMD) at 4.3% of the reported portfolio.
Bellevue Group AG reported a 13F portfolio worth $4.52B across 142 positions for Q2 2026. That is up 13.8% from the previous quarter.
Its largest purchases by value were Amgen Inc ($201.41M), INSMED Inc ($147.50M), Gilead Sciences, Inc. ($124.94M). It opened 16 new positions.
Its largest sales by value were Krystal Biotech, Inc. ($150.25M), Revolution Medicines, Inc. ($92.97M), Regeneron Pharmaceuticals, Inc. ($75.69M). It exited 22 positions entirely.
From the Form 13F-HR reports Bellevue Group AG files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.